


KRAS G12C inhibitor 19

Cat. No.:	HY-132980		
CAS No.:	2649788-46-3		
Molecular Formula:	C ₂₅ H ₁₉ ClF ₂ N ₄ O ₃ S		
Molecular Weight:	528.96		
Target:	Ras		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (236.31 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
			1 mM	1.8905 mL	9.4525 mL	18.9050 mL
			5 mM	0.3781 mL	1.8905 mL	3.7810 mL
			10 mM	0.1891 mL	0.9453 mL	1.8905 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 12.5 mg/mL (23.63 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 12.5 mg/mL (23.63 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	KRAS G12C inhibitor 19 is a potent inhibitor of KRAS G12C. KRAS G12C inhibitor 19 significantly inhibits tumor growth (extracted from patent WO2021118877A1) ^[1] .
IC ₅₀ & Target	KRAS G12C ^[1]

REFERENCES

[1]. Serge Louis Boulet, et al. Kras g12c inhibitors. Patent WO2021118877A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA